Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept

• Verfasst von: Hoffmann, Jochen [VerfasserIn]
• Verfasst von: Knoop, Christian [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Verfasst von: Hadaschik, Eva [VerfasserIn]
• Titel: Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept
• Titelzusatz: a retrospective investigation of 146 psoriasis patients
• Verf.angabe: Jochen H.O. Hoffmann, Christian Knoop, Alexander H. Enk, Eva N. Hadaschik
• E-Jahr: 2014
• Jahr: 28 September 2014
• Umfang: 6 S.
• Fussnoten: Gesehen am 21.10.2020
• Titel Quelle: Enthalten in: Journal of dermatological science
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1990
• Jahr Quelle: 2014
• Band/Heft Quelle: 76(2014), 3, Seite 180-185
• ISSN Quelle: 1873-569X
• DOI: doi:10.1016/j.jdermsci.2014.09.003
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Autoantibodies
• Sach-SW: Biomarkers
• Sach-SW: Psoriasis
• Sach-SW: TNF-α antagonist
• K10plus-PPN: 1736072889

Abstract

Background - Adalimumab and Etanercept are TNF-α antagonists commonly used for treatment of moderate-to-severe psoriasis and psoriatic-arthritis. Reliable instruments to assist the selection of patients for a specific treatment in a real-world scenario are unavailable. - Objective - To identify patient characteristics and baseline laboratory parameters predicting response to Adalimumab- and Etanercept-treatment. - Methods - We report a retrospective observational study including 116 and 64 psoriasis-patients treated with Adalimumab and Etanercept, respectively, at a dermatological outpatient clinic of a university hospital. Thirty four patients contributed data to both biologics. First occurrence of either loss-of-response or serious-side-effects (LOR/SSE) was chosen as clinical endpoint and predictors were identified using Cox-regression. - Results - Baseline anti-double-stranded DNA (anti-dsDNA) concentrations, number of previous treatments with TNF-α antagonists in general and previous treatment with Etanercept in particular significantly predicted LOR/SSE to Adalimumab. The predictive effect of baseline anti-dsDNA was conserved in TNF-α antagonist naïve patients. Number of previous systemic treatments other than TNF-α antagonists significantly predicted LOR/SSE to Etanercept. Age and baseline psoriasis area and severity index (PASI) did not predict response to either biologic in a clinically significant manner. - Conclusion - Our data suggests that treatment with Adalimumab may promise best results in psoriasis-patients with (A) low baseline anti-dsDNA concentrations, and (B) no previous TNF-α antagonist treatment. A clinically significant predictive effect of age and baseline PASI on response to Adalimumab and Etanercept is unlikely.